Immune System Diseases

CRISPR may enable rapid, sensitive test for COVID-19

The device has the potential for use as a diagnostic test at the point of care (POC), according to its developers.

September 26, 2022

N-antigen levels point to COVID severity in NIH study

The study by researchers at the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) was a cross-sectional follow-up analysis involving 2,540 participants who had been previously enrolled in the Therapeutics for Inpatients with COVID-19 (TICO) platform trial.

September 8, 2022

Lunaphore, Nucleai to provide AI-based spatial biology analysis

Combining Lunaphore's Comet hyperplex staining and imaging platform, a fully automated sequential immunofluorescence (seqIF) instrument, with Nucleai's Atom artificial-intelligence (AI) spatial biology platform will enable the companies to generate new insights from tissue biopsies and provide labs with an integrated end-to-end spatial biology workflow.

September 8, 2022

Week in Review: Room-temperature CRISPR, Roche T-cell test for COVID response, Qiagen monkeypox syndromic panel, and more

Dear LabPulse.com member,

August 17, 2022

Qiagen marks milestone for TB blood test

The fourth-generation QuantiFeronTB Gold Plus assay is being used to test patients in over 130 countries, the company said. It identifies interferon-gamma released by T cells after recognizing TB-specific antigens as a marker of TB infection.

March 23, 2022

'Rogue antibodies' hint at severe COVID risk

The goal of the study was to identify circulating factors, such as hormones and antibodies, in COVID-19 patients that contribute to the activation and dysfunction of endothelial cells, which are the main type of cell found in the inside lining of blood vessels, lymph vessels, and the heart.

February 16, 2022

Most Popular

Genetic causes identified for three rare diseases

Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease

SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests

Duke University researchers discover biomarkers may identify early pancreatic cancer risk

Werfen completes $2B acquisition of Immucor, expands presence in specialized diagnostics

Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition

AMP 2021 meeting puts spotlight back on cancer

Seminars at AMP 2021 focused on technologies and techniques to help detect and profile tumors, with special emphasis on hard-to-detect cancer cells that remain in patients after treatment.

November 22, 2021

Qiagen debuts solution for SARS-CoV-2 T-cell research

QuantiFeron SARS-CoV-2 ROU is a modular system based on the platform Qiagen developed for its QuantiFeron-TB Gold Plus test for latent tuberculosis.

December 6, 2020

Vaccines won't eliminate the need for COVID-19 testing

It may be natural to suspect that if a vaccine is available, there will be fewer cases thus less reason to test. But this isn't normally the interplay between vaccines and diseases.

November 23, 2020

Who should get the 1st COVID-19 vaccines?

Current strategic prioritization plans emphasize the importance of vaccinating healthcare workers, since doing so preserves the healthcare system itself. Another priority is to directly protect the elderly and people with comorbidities, who are at the highest risk of death or hospitalization from COVID-19.

October 25, 2020

Interleukin-6 testing grows rapidly, with limited evidence of utility

Cytokines are small proteins released by many different types of cells, including the white blood cells of the immune system. Cytokines help regulate the immune system's response to an infection and cause inflammation. The storm happens when the release of cytokines goes into an uncontrolled overdrive causing hyperinflammation which damages the body's organs. In the lungs, this inflammation causes fluid to accumulate in the airspaces which then leads to ARDS.

June 8, 2020

Sequencing seeks to stay ahead of new COVID-19 surges

Sequencing has been an essential tool for the development of strategies and therapeutics in the fight against COVID-19, and sequencing-based rapid and high-throughput diagnostics for COVID-19 are in development. Sequencing technology suppliers are collaborating with researchers to develop sequencing-based diagnostic tools. For example, several groups are using Illumina's next-generation sequencing (NGS) technology to develop ultrahigh-throughput COVID-19 diagnostic testing.

June 7, 2020

Page 1 of 3

Next Page